Still NAAG'ing After All These Years. The Continuing Pursuit of GCPII Inhibitors.

Advances in Pharmacology

Volumn 76, Issue , 2016, Pages 215-255

  Vornov, J J ^a,c   Hollinger, K R ^a   Jackson, P F ^b   Wozniak, K M ^a   Farah, M H ^a   Majer, P ^d   Rais, R ^a   Slusher, B S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Medpace ^*  (United States)

^d INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

GCPII; Glutamate; MGlu3; NAAG; NAAG peptidase; NAALADase; NMDA; NR2A; NR2B

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HYDROXAMIC ACID; METABOTROPIC RECEPTOR 3; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PHOSPHINIC ACID DERIVATIVE; SYNTHETASE; THIOL DERIVATIVE; UREA; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DIPEPTIDE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; ISOSPAGLUMIC ACID; MEMBRANE ANTIGEN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AXON; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHOLINERGIC SYSTEM; DRUG DEPENDENCE; DRUG PENETRATION; ENERGY METABOLISM; GABAERGIC SYSTEM; GLUTAMATERGIC SYNAPSE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NORADRENERGIC NERVE CELL; PAIN; PERIPHERAL NEUROPATHY; PHARMACOKINETICS; PRESYNAPTIC POTENTIAL; SCHIZOPHRENIA; SYNAPSE; SYNAPSE VESICLE; TRANSIENT ISCHEMIC ATTACK; ANIMAL; ANTAGONISTS AND INHIBITORS; GLIA; METABOLISM;

ANIMALS; ANTIGENS, SURFACE; DIPEPTIDES; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; HUMANS; NEUROGLIA; NEUROTRANSMITTER AGENTS;

EID: 84961226691     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/bs.apha.2016.01.007     Document Type: Chapter

References (181)

1. Adedoyin M.O., Vicini S., Neale J.H. Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. Molecular Pain 2010, 6:60. 10.1186/1744-8069-6-60.
2. Agarwal N., Renshaw P.F. Proton MR spectroscopy-detectable major neurotransmitters of the brain: Biology and possible clinical applications. AJNR. American Journal of Neuroradiology 2012, 33:595-602.
3. Alt J., Stathis M., Rojas C., Slusher B. Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme. FASEB Journal 2013, 27(7):2620-2625. 10.1096/fj.12-225102.
4. Arun P., Madhavarao C.N., Moffett J.R., Namboodiri M.A. Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators. Journal of Neurochemistry 2006, 98(6):2034-2042. 10.1111/j.1471-4159.2006.04068.x.
5. Auditore J.V., Olson E.J., Wade L. Isolation, purification, and probable structural configuration of N-acetyl aspartyl glutamate in human brain. Archives of Biochemistry and Biophysics 1966, 114(3):452-458. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/5957701.
6. Bacich D.J., Wozniak K.M., Lu X.C., O'Keefe D.S., Callizot N., Heston W.D., Slusher B.S. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. Journal of Neurochemistry 2005, 95(2):314-323. 10.1111/j.1471-4159.2005.03361.x.
7. Barinka C., Hlouchova K., Rovenska M., Majer P., Dauter M., Hin N., Lubkowski J. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. Journal of Molecular Biology 2008, 376(5):1438-1450. 10.1016/j.jmb.2007.12.066.
8. Barinka C., Rojas C., Slusher B., Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Current Medicinal Chemistry 2012, 19(6):856-870. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/22214450.
9. Barinka C., Rovenska M., Mlcochova P., Hlouchova K., Plechanovova A., Majer P., Lubkowski J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. Journal of Medicinal Chemistry 2007, 50(14):3267-3273. 10.1021/jm070133w.
10. Baslow M.H. An answer to "the nagging question of the function of N-acetylaspartylglutamate". Neuroscience Communications 2015, 1(1):2-7. 10.14800/nc.844.
11. Baslow M.H., Dyakin V.V., Nowak K.L., Hungund B.L., Guilfoyle D.N. 2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: Evidence of a link between neuron NAAG release and hyperemia. Journal of molecular neuroscience: MN 2005, 26(1):1-15. 10.1385/JMN:26:1:001.
12. Battaglia G., Riozzi B., Bucci D., Di Menna L., Molinaro G., Pallottino S., Bruno V. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease 2015, 74:126-136. 10.1016/j.nbd.2014.11.012.
13. Becker I., Lodder J., Gieselmann V., Eckhardt M. Molecular characterization of N-acetylaspartylglutamate synthetase. Journal of Biological Chemistry 2010, 285(38):29156-29164. 10.1074/jbc.M110.111765.
14. Bernards C.M., Akers T. Effect of postinjury intravenous or intrathecal methylprednisolone on spinal cord excitatory amino-acid release, nitric oxide generation, PGE2 synthesis, and myeloperoxidase content in a pig model of acute spinal cord injury. Spinal Cord 2006, 44(10):594-604. 10.1038/sj.sc.3101891.
15. Bischofberger J., Schild D. Glutamate and N-acetylaspartylglutamate block HVA calcium currents in frog olfactory bulb interneurons via an mGluR2/3-like receptor. Journal of Neurophysiology 1996, 76(3):2089-2092. Retrieved from. http://jn.physiology.org/jn/76/3/2089.full.pdf.
16. Bleakman D., Alt A., Nisenbaum E.S. Glutamate receptors and pain. Seminars in Cell and Developmental Biology 2006, 17(5):592-604. S1084-9521(06)00112-1 [pii]. 10.1016/j.semcdb.2006.10.008.
17. Boltshauser E., Schmitt B., Wevers R.A., Engelke U., Burlina A.B., Burlina A.P. Follow-up of a child with hypoacetylaspartia. Neuropediatrics 2004, 35(4):255-258. 10.1055/s-2004-821036.
18. Cangro C.B., Namboodiri M.A., Sklar L.A., Corigliano-Murphy A., Neale J.H. Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. Journal of Neurochemistry 1987, 49(5):1579-1588.
19. Cannella N., Halbout B., Uhrig S., Evrard L., Corsi M., Corti C., Spanagel R. The mGluR2/3 agonist LY379268 induced anti-reinstatement effects in rats exhibiting addiction-like behavior. Neuropsychopharmacology 2013, 38(10):2048-2056. 10.1038/npp.2013.106.
20. Carozzi V.A., Chiorazzi A., Canta A., Lapidus R.G., Slusher B.S., Wozniak K.M., Cavaletti G. Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotoxicity Research 2010, 17(4):380-391. 10.1007/s12640-009-9114-1.
21. Carpenter K.J., Sen S., Matthews E.A., Flatters S.L., Wozniak K.M., Slusher B.S., Dickenson A.H. Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: An electrophysiological study in the rat. Neuropeptides 2003, 37(5):298-306. S0143417903000866 [pii].
22. Castellano G., Dias C.S.B., Foerster B., Li L.M., Covolan R.J.M. NAA and NAAG variation in neuronal activation during visual stimulation. Brazilian Journal of Medical and Biological Research 2012, 45(11):1031-1036. 10.1590/S0100-879X2012007500128.
23. Chen X.Q., Fawcett J.R., Rahman Y.E., Ala T.A., Frey I.W. Delivery of nerve growth factor to the brain via the olfactory pathway. Journal of Alzheimer's Disease 1998, 1(1):35-44. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12214010.
24. Chen S.R., Wozniak K.M., Slusher B.S., Pan H.L. Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. Journal of Pharmacology and Experimental Therapeutics 2002, 300(2):662-667. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11805230.
25. Collard F., Stroobant V., Lamosa P., Kapanda C.N., Lambert D.M., Muccioli G.G., Van Schaftingen E. Molecular identification of N-acetylaspartylglutamate synthase and β-citrylglutamate synthase. Journal of Biological Chemistry 2010, 285(39):29826-29833. 10.1074/jbc.M110.152629.
26. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology and Toxicology 1997, 37:205-237. 10.1146/annurev.pharmtox.37.1.205.
27. Coyle J.T. The nagging question of the function of N-acetylaspartylglutamate. Neurobiology of Disease 1997, 4(3-4):231-238. 10.1006/nbdi.1997.0153.
28. Curatolo A., D Arcangelo P., Lino A., Brancati A. Distribution of N-acetyl-aspartic and N-acetyl-aspartyl-glutamic acids in nervous tissue. Journal of Neurochemistry 1965, 12:339-342. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/14340686.
29. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. Journal of Pharmaceutical Sciences 2009, 99(4):1654-1673. 10.1002/jps.21924.
30. Durand D., Carniglia L., Caruso C., Lasaga M. MGlu3 receptor and astrocytes: Partners in neuroprotection. Neuropharmacology 2013, 66:1-11. 10.1016/j.neuropharm.2012.04.009.
31. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(34):12604-12609. 10.1073/pnas.0405077101.
32. Ellaithy A., Younkin J., González-Maeso J., Logothetis D.E. Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment. Trends in Neurosciences 2015, 38(8). 10.1016/j.tins.2015.06.002.
33. Faden A.I., Demediuk P., Panter S.S., Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989, 244(4906):798-800. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/2567056.
34. Feng J.F., Gurkoff G.G., Van K.C., Song M., Lowe D.A., Zhou J., Lyeth B.G. NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. Brain Research 2012, 1469:144-152. 10.1016/j.brainres.2012.06.021.
35. Feng J.F., Van K.C., Gurkoff G.G., Kopriva C., Olszewski R.T., Song M., Lyeth B.G. Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. Brain Research 2011, 1395:62-73. S0006-8993(11)00738-4 [pii]. 10.1016/j.brainres.2011.04.022.
36. Ferraris D.V., Shukla K., Tsukamoto T. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. Current Medicinal Chemistry 2012, 19(9):1282-1294. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/22304717.
37. Fisher K., Coderre T.J. Comparison of nociceptive effects produced by intrathecal administration of mGluR agonists. Neuroreport 1996, 7(15-17):2743-2747. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8981459.
38. Flores C., Coyle J.T. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology 2003, 28(7):1227-1234. 10.1038/sj.npp.1300129.
39. Forloni G., Grzanna R., Blakely R.D., Coyle J.T. Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse (New York, N.Y.) 1987, 1(5):455-460. 10.1002/syn.890010509.
40. Frey W., Liu J., Chen X., Thorne R.G., Fawcett J.R., Ala T.A., Rahman Y.E. Delivery of 125I-NGF to the brain via the olfactory route. Drug Delivery 1997, 4:87-92.
41. Fricker A.C., Mok M.H., de la Flor R., Shah A.J., Woolley M., Dawson L.A., Kew J.N. Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 2009, 56(6-7):1060-1067. 10.1016/j.neuropharm.2009.03.002.
42. Frondoza C.G., Logan S., Forloni G., Coyle J.T. Production and characterization of monoclonal antibodies to N-acetyl-aspartyl-glutamate. Journal of Histochemistry and Cytochemistry 1990, 38(4):493-502. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/2319120.
43. Gafurov B., Urazaev A.K., Grossfeld R.M., Lieberman E.M. N-acetylaspartylglutamate (NAAG) is the probable mediator of axon-to-glia signaling in the crayfish medial giant nerve fiber. Neuroscience 2001, 106(1):227-235. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11564432.
44. Gao Y., Xu S., Cui Z., Zhang M., Lin Y., Cai L., Zhong C. Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury. Journal of Neurochemistry 2015, 134(2):340-353. 10.1111/jnc.13123.
45. Gehl L.M., Saab O.H., Bzdega T., Wroblewska B., Neale J.H. Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. Journal of Neurochemistry 2004, 90(4):989-997. 10.1111/j.1471-4159.2004.02578.x.
46. Ghadge G.D., Slusher B.S., Bodner A., Canto M.D., Wozniak K., Thomas A.G., Roos R.P. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(16):9554-9559. 1530168100 [pii]. 10.1073/pnas.1530168100.
47. Ghose S., Chin R., Gallegos A., Roberts R., Coyle J., Tamminga C. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophrenia Research 2009, 111(1-3):131-137. 10.1016/j.schres.2009.03.038.
48. Ghose S., Weickert C.S., Colvin S.M., Coyle J.T., Herman M.M., Hyde T.M., Kleinman J.E. Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology 2004, 29(1):117-125. 10.1038/sj.npp.1300304.
49. Ghose S., Wroblewska B., Corsi L., Grayson D.R., De Blas A.L., Vicini S., Neale J.H. N-acetylaspartylglutamate stimulates metabotropic glutamate receptor 3 to regulate expression of the GABA(A) alpha6 subunit in cerebellar granule cells. Journal of Neurochemistry 1997, 69(6):2326-2335. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/9375663.
50. Goudet C., Magnaghi V., Landry M., Nagy F., Gereau R.W., Pin J.P. Metabotropic receptors for glutamate and GABA in pain. Brain Research Reviews 2009, 60(1):43-56. S0165-0173(08)00145-8 [pii]. 10.1016/j.brainresrev.2008.12.007.
51. Grella B., Adams J., Berry J.F., Delahanty G., Ferraris D.V., Majer P., Tsukamoto T. The discovery and structure-activity relationships of indole-based inhibitors of glutamate carboxypeptidase II. Bioorganic and Medicinal Chemistry Letters 2010, 20(24):7222-7225. 10.1016/j.bmcl.2010.10.109.
52. Guilarte T.R., Hammoud D.A., McGlothan J.L., Caffo B.S., Foss C.A., Kozikowski A.P., Pomper M.G. Dysregulation of glutamate carboxypeptidase II in psychiatric disease. Schizophrenia Research 2008, 99(1-3):324-332. 10.1016/j.schres.2007.11.013.
53. Gurkoff G.G., Feng J.F., Van K.C., Izadi A., Ghiasvand R., Shahlaie K., Lyeth B.G. NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia. Brain Research 2013, 1515:98-107. 10.1016/j.brainres.2013.03.043.
54. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clinical Neuropharmacology 1995, 18(3):237-249. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/8635182.
55. Harada C., Harada T., Slusher B.S., Yoshida K., Matsuda H., Wada K. N-acetylated-alpha-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia. Neuroscience Letters 2000, 292(2):134-136. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/10998567.
56. Hollinger K.R., Alt J., Riehm A.M., Slusher B.S., Kaplin A.I. Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis. Brain Research 2016, Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/26826008, 10.1016/j.brainres.2016.01.035.
57. Jaarsma D., Veenma-van der Duin L., Korf J. N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue. Journal of Neurological Sciences 1994, 127(2):230-233. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/7707082.
58. Jackson P.F., Cole D.C., Slusher B.S., Stetz S.L., Ross L.E., Donzanti B.A., Trainor D.A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. Journal of Medicinal Chemistry 1996, 39(2):619-622. 10.1021/jm950801q.
59. Jackson P.F., Tays K.L., Maclin K.M., Ko Y.S., Li W., Vitharana D., Slusher B.S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. Journal of Medicinal Chemistry 2001, 44(24):4170-4175. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11708918.
60. Janczura K.J., Olszewski R.T., Bzdega T., Bacich D.J., Heston W.D., Neale J.H. NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test. European Journal of Pharmacology 2013, 701(1-3):27-32. 10.1016/j.ejphar.2012.11.027.
61. Jessen F., Fingerhut N., Sprinkart A.M., Kuhn K.U., Petrovsky N., Maier W., Traber F. N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. Schizophrenia Bulletin 2013, 39(1):197-205. 10.1093/schbul/sbr127.
62. Johnson E.C. N-acetylaspartylglutamate is not demonstrated to be a selective mGlu receptor agonist. Journal of Neurochemistry 2011, 119(5):896-898. 10.1111/j.1471-4159.2011.07480.x.
63. Johnson N.J., Hanson L.R., Frey W.H. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Molecular Pharmaceutics 2010, 7(3):884-893. 10.1021/mp100029t.
64. Kaiser E., Schoenknecht P., Kassner S., Hildebrandt W., Kinscherf R., Schroeder J. Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease. Neurodegenerative Diseases 2010, 7(4):251-259. 10.1159/000287953.
65. Katsutani N., Shionoya H. Drug-specific immune responses induced by immunization with drugs in guinea pigs and mice. The Journal of Toxicological Sciences 1992, 17(4):169-183. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/1474612.
66. Khacho P., Wang B., Ahlskog N., Hristova E., Bergeron R. Differential effects of N-acetyl-aspartyl-glutamate on synaptic and extrasynaptic NMDA receptors are subunit- and pH-dependent in the CA1 region of the mouse hippocampus. Neurobiology of Disease 2015, 10.1016/j.nbd.2015.08.017.
67. Kim M.J., Chae S.S., Koh Y.H., Lee S.K., Jo S.A. Glutamate carboxypeptidase II: An amyloid peptide-degrading enzyme with physiological function in the brain. FASEB Journal 2010, 24(11):4491-4502. fj.09-148825 [pii]. 10.1096/fj.09-148825.
68. Koller K.J., Zaczek R., Coyle J.T. N-acetyl-aspartyl-glutamate: Regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. Journal of Neurochemistry 1984, 43(4):1136-1142. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/6470709.
69. Kozela E., Wrobel M., Kos T., Wojcikowski J., Daniel W.A., Wozniak K.M., Popik P. 2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice. Psychopharmacology 2005, 183(3):275-284. 10.1007/s00213-005-0182-5.
70. Kozikowski A.P., Nan F., Conti P., Zhang J., Ramadan E., Bzdega T., Wroblewski J.T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). Journal of Medicinal Chemistry 2001, 44(3):298-301. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11462970.
71. Kozikowski A.P., Zhang J., Nan F., Petukhov P.A., Grajkowska E., Wroblewski J.T., Neale J.H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents. Journal of Medicinal Chemistry 2004, 47(7):1729-1738. 10.1021/jm0306226.
72. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994, 51(3):199-214. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/8122957.
73. Lapi S.E., Wahnishe H., Pham D., Wu L.Y., Nedrow-Byers J.R., Liu T., Jones E.F. Assessment of an 18 F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Journal of Nuclear Medicine 2009, 50(12):2042-2048. 10.2967/jnumed.109.066589.
74. Lea P.M., Wroblewska B., Sarvey J.M., Neale J.H. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. Journal of Neurophysiology 2001, 85(3):1097-1106. Retrieved from. http://jn.physiology.org/jn/85/3/1097.full.pdf.
75. Ley C.R., Beattie N.R., Dannoon S., Regan M., VanBrocklin H., Berkman C.E. Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen. Bioorganic and Medicinal Chemistry Letters 2015, 25(12):2536-2539. 10.1016/j.bmcl.2015.04.047.
76. Li M.-L., Hu X.-Q., Li F., Gao W.-J. Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015, 60:66-76. 10.1016/j.pnpbp.2015.02.012.
77. Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews 2011, 64(7):614-628. S0169-409X(11)00279-1 [pii]. 10.1016/j.addr.2011.11.002.
78. Lodder-Gadaczek J., Gieselmann V., Eckhardt M. Vesicular uptake of N-acetylaspartylglutamate is catalysed by sialin (SLC17A5). The Biochemical Journal 2013, 454(1):31-38. 10.1042/BJ20130300.
79. Long J.B., Yourick D.L., Slusher B.S., Robinson M.B., Meyerhoff J.L. Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. European Journal of Pharmacology 2005, 508(1-3):115-122. S0014-2999(04)01408-6 [pii]. 10.1016/j.ejphar.2004.12.008.
80. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. The Neuroscientist: A Review Journal Bringing Neurobiology, Neurology and Psychiatry 2009, 15(5):525-539. 10.1177/1073858409336093.
81. Madayag A., Lobner D., Kau K.S., Mantsch J.R., Abdulhameed O., Hearing M., Baker D.A. Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. Journal of Neuroscience 2007, 27(51):13968-13976. 10.1523/JNEUROSCI.2808-07.2007.
82. Majer P., Hin B., Stoermer D., Adams J., Xu W., Duvall B.R., Tsukamoto T. Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. Journal of Medicinal Chemistry 2006, 49(10):2876-2885. 10.1021/jm051019l.
83. Majer P., Jackson P.F., Delahanty G., Grella B.S., Ko Y.S., Li W., Tsukamoto T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: Discovery of an orally active GCP II inhibitor. Journal of Medicinal Chemistry 2003, 46(10):1989-1996. 10.1021/jm020515w.
84. Malomouzh A.I., Nikolsky E.E., Lieberman E.M., Sherman J.a., Lubischer J.L., Grossfeld R.M., Urazaev A.K. Effect of N-acetylaspartylglutamate (NAAG) on non-quantal and spontaneous quantal release of acetylcholine at the neuromuscular synapse of rat. Journal of Neurochemistry 2005, 94(1):257-267. 10.1111/j.1471-4159.2005.03194.x.
85. Maresca K.P., Hillier S.M., Femia F.J., Keith D., Barone C., Joyal J.L., Babich J.W. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. Journal of Medicinal Chemistry 2009, 52(2):347-357. 10.1021/jm800994j.
86. Marmiroli P., Slusher B., Cavaletti G. Tissue distribution of glutamate carboxypeptidase II (GCPII) with a focus on the central and peripheral nervous system. Current Medicinal Chemistry 2012, 19(9):1277-1281. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/22304706.
87. Martin E., Capone A., Schneider J., Hennig J. Absence of N-acetylaspartate in the human brain: Impact on neurospectroscopy?. Annals of Neurology 2001, 49:518-543.
88. Mease R.C., Foss C.A., Pomper M.G. PET imaging in prostate cancer: Focus on prostate-specific membrane antigen. Current Topics in Medicinal Chemistry 2013, 13(8):951-962. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/23590171.
89. Mendes D.E., Wong-On-Wing A., Berkman C.E. Phosphoramidate-based peptidomimetic inhibitors of membrane type-1 matrix metalloproteinase. Journal of Enzyme Inhibition and Medicinal Chemistry 2015, 31:167-171. 10.3109/14756366.2015.1010528.
90. Mesters J.R., Barinka C., Li W., Tsukamoto T., Majer P., Slusher B.S., Hilgenfeld R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO Journal 2006, 25(6):1375-1384. 10.1038/sj.emboj.7600969.
91. Meyerhoff J.L., Carter R.E., Yourick D.L., Slusher B.S., Coyle J.T. Genetically epilepsy-prone rats have increased brain regional activity of an enzyme which liberates glutamate from N-acetyl-aspartyl-glutamate. Brain Research 1992, 593(1):140-143. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/1360862.
92. Miyake M., Kakimoto Y., Sorimachi M. A gas chromatographic method for the determination of N-acetyl-L-aspartic acid, N-acetyl-alpha-aspartylglutamic acid and beta-citryl-L-glutamic acid and their distributions in the brain and other organs of various species of animals. Journal of Neurochemistry 1981, 36(3):804-810. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/7205274.
93. Miyamoto E., Kakimoto Y., Sano I. Identification of N-acetyl-alpha-aspartylglutamic acid in the bovine brain. Journal of Neurochemistry 1966, 13(10):999-1003.
94. Miyamoto E., Tsujio T. Determination of N-acetyl-alpha-aspartyl-glutamic acid in the nervous tissue of mammals. Journal of Neurochemistry 1967, 14(9):899-903. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/6069284.
95. Mlcochova P., Plechanovova A., Barinka C., Mahadevan D., Saldanha J.W., Rulisek L., Konvalinka J. Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. The FEBS Journal 2007, 274(18):4731-4741. 10.1111/j.1742-4658.2007.06021.x.
96. Nagel J., Belozertseva I., Greco S., Kashkin V., Malyshkin A., Jirgensons A., Danysz W. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain-Relation to brain concentration. Neuropharmacology 2006, 51(7-8):1163-1171. S0028-3908(06)00227-9 [pii]. 10.1016/j.neuropharm.2006.07.018.
97. Narayan R.K., Michel M.E., Ansell B., Baethmann A., Biegon A., Bracken M.B., Yurkewicz L. Clinical trials in head injury. Journal of Neurotrauma 2002, 19(5):503-557. 10.1089/089771502753754037.
98. Novakova Z., Cerny J., Choy C.J., Nedrow J., Choi J.K., Lubkowski J., Barinka C. Design of composite inhibitors targeting glutamate carboxypeptidase II: The importance of effector functionalities. The FEBS Journal 2015, 10.1111/febs.13557.
99. Olszewski R.T., Bukhari N., Zhou J., Kozikowski A.P., Wroblewski J.T., Shamimi-Noori S., Neale J.H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. Journal of Neurochemistry 2004, 89(4):876-885. 10.1111/j.1471-4159.2004.02358.x.
100. Olszewski R.T., Bzdega T., Neale J.H. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophrenia Research 2012, 136(1-3):160-161. 10.1016/j.schres.2012.01.007.
101. Olszewski R.T., Janczura K.J., Ball S.R., Madore J.C., Lavin K.M., Lee J.C., Neale J.H. NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Translational Psychiatry 2012, 2:e145. 10.1038/tp.2012.68.
102. Olszewski R.T., Wegorzewska M.M., Monteiro A.C., Krolikowski K.A., Zhou J., Kozikowski A.P., Neale J.H. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biological Psychiatry 2008, 63(1):86-91. 10.1016/j.biopsych.2007.04.016.
103. Passani L., Elkabes S., Coyle J.T. Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia. Brain Research 1998, 794(1):143-145. 10.1016/S0006-8993(98)00308-4.
104. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Molecular and Chemical Neuropathology 1997, 31(2):97-118. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9376025.
105. Passani L.a., Vonsattel J.P.G., Coyle J.T. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Research 1997, 772(1-2):9-22. 10.1016/S0006-8993(97)00784-1.
106. Peng X.Q., Li J., Gardner E.L., Ashby C.R., Thomas A., Wozniak K., Xi Z.X. Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. European Journal of Pharmacology 2010, 627(1-3):156-161. 10.1016/j.ejphar.2009.10.062.
107. Peters J., Kalivas P.W. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology 2006, 186(2):143-149. 10.1007/s00213-006-0372-9.
108. Plaitakis A., Caroscio J.T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Annals of Neurology 1987, 22(5):575-579. 10.1002/ana.410220503.
109. Popik P., Kozela E., Wrobel M., Wozniak K.M., Slusher B.S. Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA. Neuropsychopharmacology 2003, 28(3):457-467. 10.1038/sj.npp.1300048.
110. Potter M.C., Wozniak K.M., Callizot N., Slusher B.S. Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats. PLoS One 2014, 9(9):e102936. 10.1371/journal.pone.0102936.
111. Pulvirenti L., Maldonado-Lopez R., Koob G.F. NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Research 1992, 594(2):327-330. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/1360323.
112. Puttfarcken P.S., Handen J.S., Montgomery D.T., Coyle J.T., Werling L.L. N-acetyl-aspartylglutamate modulation of N-methyl-D-aspartate-stimulated [H-3] norepinephrine release from rat hippocampal slices. Journal of Pharmacology and Experimental Therapeutics 1993, 266(2):796-803. Retrieved from Go to ISI://WOS:A1993LT48200044. http://jpet.aspetjournals.org/content/266/2/796.full.pdf.
113. Rahn K.A., Watkins C.C., Alt J., Rais R., Stathis M., Grishkan I., Kaplin A.I. Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(49):20101-20106. 10.1073/pnas.1209934109.
114. Rais R., Wozniak K., Wu Y., Niwa M., Stathis M., Alt J., Slusher B.S. Selective CNS uptake of the GCP-II inhibitor 2-PMPA following intranasal administration. PLoS One 2015, 10(7):e0131861. 10.1371/journal.pone.0131861.
115. Rich D. Peptidase inhibitors. Comprehensive medicinal chemistry 1990, Vol. 3:391-441. Pergamon Press, New York, 1st ed.
116. Ripke S., Neale B.M., Corvin A., Walters J.T.R., Farh K.-H., Holmans P.A., O'Donovan M.C. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427. 10.1038/nature13595.
117. Robinson M.B., Blakely R.D., Couto R., Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. Journal of Biological Chemistry 1987, 262(30):14498-14506. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/3667587.
118. Romei C., Raiteri M., Raiteri L. Glycine release is regulated by metabotropic glutamate receptors sensitive to mGluR2/3 ligands and activated by N-acetylaspartylglutamate (NAAG). Neuropharmacology 2013, 66:311-316. 10.1016/j.neuropharm.2012.05.030.
119. Rothstein J.D., Martin L.J., Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New England Journal of Medicine 1992, 326(22):1464-1468. 10.1056/NEJM199205283262204.
120. Rothstein J.D., Tsai G., Kuncl R.W., Clawson L., Cornblath D.R., Drachman D.B., Coyle J.T. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Annals of Neurology 1990, 28(1):18-25. 10.1002/ana.410280106.
121. Schoepp D.D., Johnson B.G., Monn J.A. Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist. Journal of Neurochemistry 1992, 58(3):1184-1186. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/1310724.
122. Sedlak F., Sacha P., Blechova M., Brezinova A., Safarik M., Sebestik J., Konvalinka J. Glutamate carboxypeptidase II does not process amyloid-beta peptide. FASEB Journal 2013, 27(7):2626-2632. 10.1096/fj.12-225094.
123. Sekiguchi M., Okamoto K., Sakai Y. Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of purkinje-cells in guinea-pig cerebellar slices and the responses to excitatory amino-acids of Xenopus-laevis oocytes injected with cerebellar messenger-RNA. Brain Research 1989, 482(1):87-96. 10.1016/0006-8993(89)90545-3.
124. Shaw P.J., Forrest V., Ince P.G., Richardson J.P., Wastell H.J. CSF and plasma amino acid levels in motor neuron disease: Elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995, 4(2):209-216. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/7583686.
125. Shetty P.K., Galeffi F., Turner D.A. Cellular links between neuronal activity and energy homeostasis. Frontiers in Pharmacology 2012, 3:43. 10.3389/fphar.2012.00043.
126. Shippenberg T.S., Rea W., Slusher B.S. Modulation of behavioral sensitization to cocaine by NAALADase inhibition. Synapse 2000, 38(2):161-166. 10.1002/1098-2396(200011)38:2 161::AID-SYN7 3.0.CO;2-G.
127. Slusher B.S., Robinson M.B., Tsai G., Simmons M.L., Richards S.S., Coyle J.T. Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. Journal of Biological Chemistry 1990, 265(34):21297-21301. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/2250024.
128. Slusher B.S., Vornov J.J., Thomas A.G., Hurn P.D., Harukuni I., Bhardwaj A., Jackson P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nature Medicine 1999, 5(12):1396-1402. 10.1038/70971.
129. Small D.L., Buchan A.M. NMDA antagonists: Their role in neuroprotection. International Review of Neurobiology 1997, 40:137-171. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/8989620.
130. Stevens J., Ploeger B.A., van der Graaf P.H., Danhof M., de Lange E.C. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metabolism and Disposition 2011, 39(12):2275-2282. dmd.111.040782 [pii]. 10.1124/dmd.111.040782.
131. Stoermer D., Liu Q., Hall M.R., Flanary J.M., Thomas A.G., Rojas C., Tsukamoto T. Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorganic and Medicinal Chemistry Letters 2003, 13(13):2097-2100. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/12798312.
132. Stover J.F., Pleines U.E., Morganti-Kossmann M.C., Kossmann T., Lowitzsch K., Kempski O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. European Journal of Clinical Investigation 1997, 27(12):1038-1043. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/9466133.
133. Subasinghe N., Schulte M., Chan M.Y., Roon R.J., Koerner J.F., Johnson R.L. Synthesis of acyclic and dehydroaspartic acid analogues of Ac-Asp-Glu-OH and their inhibition of rat brain N-acetylated alpha-linked acidic dipeptidase (NAALA dipeptidase). Journal of Medicinal Chemistry 1990, 33(10):2734-2744. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/2213826.
134. Sulkowski G., Dabrowska-Bouta B., Struzynska L. Modulation of neurological deficits and expression of glutamate receptors during experimental autoimmune encephalomyelitis after treatment with selected antagonists of glutamate receptors. Biomed Research International 2013, 2013:186068. 10.1155/2013/186068.
135. Sun W., McConnell E., Pare J.-F., Xu Q., Chen M., Peng W., Nedergaard M. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. Science (New York, N.Y.) 2013, 339(6116):197-200. 10.1126/science.1226740.
136. Takatsu Y., Fujita Y., Tsukamoto T., Slusher B.S., Hashimoto K. Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. Brain Research 2011, 1371:82-86. 10.1016/j.brainres.2010.11.048.
137. Thomas A.G., Olkowski J.L., Slusher B.S. Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation. European Journal of Pharmacology 2001, 426(1-2):35-38. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11525768.
138. Thomas A.G., Wozniak K.M., Tsukamoto T., Calvin D., Wu Y., Rojas C., Slusher B.S. Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Advances in Experimental Medicine and Biology 2006, 576:327-337. discussion 361-323. 10.1007/0-387-30172-0_24.
139. Tomiyama M., Furusawa K., Kamijo M., Kimura T., Matsunaga M., Baba M. Upregulation of mRNAs coding for AMPA and NMDA receptor subunits and metabotropic glutamate receptors in the dorsal horn of the spinal cord in a rat model of diabetes mellitus. Brain Research. Molecular Brain Research 2005, 136(1-2):275-281. 10.1016/j.molbrainres.2005.02.003.
140. Tsai G., Forloni G., Robinson M.B., Stauch B.L., Coyle J.T. Calcium-dependent evoked release of N-[3H]acetylaspartylglutamate from the optic pathway. Journal of Neurochemistry 1988, 51(6):1956-1959.
141. Tsai G., Passani L.A., Slusher B.S., Carter R., Baer L., Kleinman J.E., Coyle J.T. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Archives of General Psychiatry 1995, 52(10):829-836. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/7575102.
142. Tsai G., Stauch B.L.L., Vornov J.J.J., Deshpande J.K.K., Coyle J.T.T. Selective release of N-acetylaspartylglutamate from rat optic nerve terminals in vivo. Brain Research 1990, 518(1-2):313-316. 10.1016/0006-8993(90)90989-O.
143. Tsai G.C., Stauch-Slusher B., Sim L., Hedreen J.C., Rothstein J.D., Kuncl R., Coyle J.T. Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Research 1991, 556(1):151-156. 10.1016/0006-8993(91)90560-I.
144. Tsukamoto, T., Liu, Q., Xu, W., Majer, P., Hin, B., & Stoermer, D. (2002). USA Patent No.: WO02092553.
145. Tsukamoto T., Majer P., Vitharana D., Ni C., Hin B., Lu X.C., Bonneville G.W. Enantiospecificity of glutamate carboxypeptidase II inhibition. Journal of Medicinal Chemistry 2005, 48(7):2319-2324. 10.1021/jm049258g.
146. Urazaev A.K., Grossfeld R.M., Fletcher P.L., Speno H., Gafurov B.S., Buttram J.G., Lieberman E.M. Synthesis and release of N-acetylaspartylglutamate (NAAG) by crayfish nerve fibers: Implications for axon-glia signaling. Neuroscience 2001, 106(1):237-247. 10.1016/S0306-4522(01)00270-6.
147. Urazaev A.K., Grossfeld R.M., Lieberman E.M. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors. Journal of Neurochemistry 2005, 93(3):605-610. 10.1111/j.1471-4159.2005.03041.x.
148. Uys J.D., LaLumiere R.T. Glutamate: The new frontier in pharmacotherapy for cocaine addiction. CNS & Neurological Disorders Drug Targets 2008, 7(5):482-491. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19128205.
149. Vaka S.R., Sammeta S.M., Day L.B., Murthy S.N. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. Journal of Pharmaceutical Sciences 2009, 98(10):3640-3646. 10.1002/jps.21674.
150. van der Post J.P., de Visser S.J., de Kam M.L., Woelfler M., Hilt D.C., Vornov J., van Gerven J.M.A. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. British Journal of Clinical Pharmacology 2005, 60(2):128-136. 10.1111/j.1365-2125.2005.02396.x.
151. Villoslada P., Arrondo G., Sepulcre J., Alegre M., Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009, 72(19):1630-1633. 10.1212/01.wnl.0000342388.73185.80.
152. Vornov J.J., Wozniak K.M., Wu Y., Rojas C., Rais R., Slusher B.S. Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism. Journal of Pharmacology and Experimental Therapeutics 2013, 346(3):406-413. 10.1124/jpet.113.205039.
153. Walder K.K., Ryan S.B., Bzdega T., Olszewski R.T., Neale J.H., Lindgren C.a. Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction. European Journal of Neuroscience 2013, 37(1):118-129. 10.1111/ejn.12027.
154. Wallstrom E., Diener P., Ljungdahl A., Khademi M., Nilsson C.G., Olsson T. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. Journal of the Neurological Sciences 1996, 137(2):89-96. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/8782160.
155. Westbrook G.L., Mayer M.L., Namboodiri M.A.A., Neale J.H. High-concentrations of N-acetylaspartylglutamate (Naag) selectively activate NMDA receptors on mouse spinal-cord neurons in cell-culture. Journal of Neuroscience 1986, 6(11):3385-3392. Retrieved from Go to ISI ://WOS:A1986E765100030. http://www.jneurosci.org/content/6/11/3385.full.pdf.
156. Williams A.J., Lu X.M., Slusher B., Tortella F.C. Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats. Journal of Pharmacology and Experimental Therapeutics 2001, 299(1):48-57. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11561062.
157. Williamson L.C., Neale J.H. Ultrastructural localization of N-acetylaspartylglutamate in synaptic vesicles of retinal neurons. Brain Research 1988, 456(2):375-381. 10.1016/0006-8993(88)90243-0.
158. Witkin J.M., Gasior M., Schad C., Zapata A., Shippenberg T., Hartman T., Slusher B.S. NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 2002, 43(3):348-356. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/12243764.
159. Wozniak K.M., Wu Y., Vornov J.J., Lapidus R., Rais R., Rojas C., Slusher B.S. The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy. The Journal of Pharmacology and Experimental Therapeutics 2012, 343(3):746-754. 10.1124/jpet.112.197665.
160. Wroblewska B., Wegorzewska I.N., Bzdega T., Olszewski R.T., Neale J.H. Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes. Journal of Neurochemistry 2006, 96(4):1071-1077. 10.1111/j.1471-4159.2005.03569.x.
161. Wroblewska B., Wroblewski J.T., Pshenichkin S., Surin a., Sullivan S.E., Neale J.H. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. Journal of Neurochemistry 1997, 69(1):174-181. 10.1046/j.1471-4159.1997.69010174.x.
162. Wroblewska B., Wroblewski J.T., Saab O.H., Neale J.H. N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. Journal of Neurochemistry 1993, 61(3):943-948. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/7689644.
163. Xi Z.X., Li X., Peng X.Q., Li J., Chun L., Gardner E.L., Ashby C.R. Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: A NAAG-mGluR2/3-mediated mechanism. Journal of Neurochemistry 2010, 112(2):564-576. 10.1111/j.1471-4159.2009.06478.x.
164. Yamada T., Zuo D., Yamamoto T., Olszewski R.T., Bzdega T., Moffett J.R., Neale J.H. NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation. Molecular Pain 2012, 8:67. 10.1186/1744-8069-8-67.
165. Yamamoto T., Hirasawa S., Wroblewska B., Grajkowska E., Zhou J., Kozikowski A., Neale J.H. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. The European Journal of Neuroscience 2004, 20(2):483-494. EJN3504 [pii]. 10.1111/j.1460-9568.2004.03504.x.
166. Yamamoto T., Kozikowski A., Zhou J., Neale J.H. Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Molecular Pain 2008, 4:31. 1744-8069-4-31 [pii]. 10.1186/1744-8069-4-31.
167. Yamamoto T., Nozaki-Taguchi N., Sakashita Y. Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Research 2001, 909(1-2):138-144. S0006-8993(01)02650-6 [pii].
168. Yamamoto T., Nozaki-Taguchi N., Sakashita Y., Inagaki T. Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 2001, 102(2):473-479. S0306-4522(00)00502-9 [pii].
169. Yamamoto T., Saito O., Aoe T., Bartolozzi A., Sarva J., Zhou J., Neale J.H. Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. The European Journal of Neuroscience 2007, 25(1):147-158. EJN5272 [pii]. 10.1111/j.1460-9568.2006.05272.x.
170. Yogeeswari P., Semwal A., Mishra R., Sriram D. Current approaches with the glutamatergic system as targets in the treatment of neuropathic pain. Expert Opinion on Therapeutic Targets 2009, 13(8):925-943. 10.1517/14728220903029210.
171. Youn S., Kim K.I., Ptacek J., Ok K., Novakova Z., Kim Y., Byun Y. Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: Synthesis and structural characterization. Bioorganic and Medicinal Chemistry Letters 2015, 10.1016/j.bmcl.2015.09.062.
172. Zaczek R., Koller K., Cotter R., Heller D., Coyle J.T. N-acetylaspartylglutamate: An endogenous peptide with high affinity for a brain "glutamate" receptor. Proceedings of the National Academy of Sciences of the United States of America 1983, 80(4):1116-1119. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/6302671.
173. Zhang W., Murakawa Y., Wozniak K.M., Slusher B., Sima A.A. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. Journal of Neurological Sciences 2006, 247(2):217-223. S0022-510X(06)00250-4 [pii]. 10.1016/j.jns.2006.05.052.
174. Zhang W., Slusher B., Murakawa Y., Wozniak K.M., Tsukamoto T., Jackson P.F., Sima A.A. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. Journal of Neurological Sciences 2002, 194(1):21-28. S0022510X01006700 [pii].
175. Zhong C., Luo Q., Jiang J. Blockade of N-acetylaspartylglutamate peptidases: A novel protective strategy for brain injuries and neurological disorders. The International Journal of Neuroscience 2014, 124(12):867-873. 10.3109/00207454.2014.890935.
176. Zhong C., Zhao X., Sarva J., Kozikowski A., Neale J.H., Lyeth B.G. NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. Journal of Neurotrauma 2005, 22(2):266-276. 10.1089/neu.2005.22.266.
177. Zhong C., Zhao X., Van K.C., Bzdega T., Smyth A., Zhou J., Lyeth B.G. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. Journal of Neurochemistry 2006, 97(4):1015-1025. 10.1111/j.1471-4159.2006.03786.x.
178. Zhou S., Bonasera L., Carlton S.M. Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. Neuroreport 1996, 7(4):895-900. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8724668.
179. Zhou H.Y., Chen S.R., Pan H.L. Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. Expert Review of Clinical Pharmacology 2011, 4(3):379-388. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21686074.
180. Zhou J., Neale J.H., Pomper M.G., Kozikowski A.P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nature Reviews Drug Discovery 2005, 4(12):1015-1026. nrd1903 [pii]. 10.1038/nrd1903.
181. Zuo D., Bzdega T., Olszewski R.T., Moffett J.R., Neale J.H. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia. Journal of Biological Chemistry 2012, 287(26):21773-21782. M112.363226 [pii]. 10.1074/jbc.M112.363226.